The Food and Drug Administration (FDA) has approved extended dosing intervals for Eylea HD ® (aflibercept) for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME ...

Results from cohort 3 of ZUMA-2 demonstrated high objective response rates and deep remissions with a safety profile consistent with previous experience for this personalized immunotherapy. The Food ...

The table below is a review of notable updates that occurred in March 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. GZR4 (Gan ...

More participants felt "much more" in control of their diabetes, eating, and weight after switching to tirzepatide vs escalating dulaglutide. HealthDay News — For adults with type 2 diabetes (T2D) who ...

Adding durvalumab and tremelimumab-actl to lenvatinib and transarterial chemoembolization significantly improved progression free survival in patients with unresectable hepatocellular carcinoma.

Expanding eligibility for full LIS to include Medicare beneficiaries with incomes between 135 and 150 percent of FPL reduces cost-related medication nonadherence HealthDay News — Expanding eligibility ...

Batoclimab did not significantly improve proptosis responder rates vs placebo in patients with thyroid eye disease at week 24. Topline data were announced from two phase 3 trials evaluating batoclimab ...

HealthDay News — Glucagon-like peptide-1 (GLP-1) receptor agonist (RA) use is associated with delayed wound healing in patients undergoing abdominal panniculectomy, according to a study published in ...

The Food and Drug Administration (FDA) has granted Fast Track designation to CDI-988 for treatment and prophylaxis of norovirus infection.

In phase 3 clinical trials, orforglipron was associated with significant reductions in mean percent body weight compared with placebo in patients with and without type 2 diabetes.